Ruffer LLP Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Ruffer LLP acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,501 shares of the company’s stock, valued at approximately $2,598,000. Ruffer LLP owned approximately 0.13% of Harmony Biosciences as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in HRMY. Creative Planning purchased a new position in shares of Harmony Biosciences during the third quarter valued at about $246,000. CWA Asset Management Group LLC purchased a new position in shares of Harmony Biosciences during the third quarter valued at about $576,000. GSA Capital Partners LLP purchased a new position in shares of Harmony Biosciences during the third quarter valued at about $235,000. Quest Partners LLC grew its position in shares of Harmony Biosciences by 137.6% during the third quarter. Quest Partners LLC now owns 35,723 shares of the company’s stock valued at $1,429,000 after purchasing an additional 20,689 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Harmony Biosciences during the third quarter valued at about $359,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Trading Down 0.1 %

NASDAQ HRMY opened at $33.67 on Friday. The company has a fifty day moving average of $36.51 and a 200 day moving average of $35.72. The company has a market capitalization of $1.93 billion, a PE ratio of 15.96, a P/E/G ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.11. The business had revenue of $201.30 million during the quarter, compared to analysts’ expectations of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 earnings per share. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HRMY. Mizuho lowered their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a report on Thursday, February 20th. HC Wainwright lowered their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, February 25th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $53.11.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 1,629 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.02, for a total value of $61,934.58. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock valued at $2,831,679 over the last 90 days. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.